Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Cash & Current Investments (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Cash & Current Investments data on record, last reported at $154.5 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 5.83% year-over-year to $154.5 million; the TTM value through Dec 2025 reached $154.5 million, down 5.83%, while the annual FY2025 figure was $154.5 million, 5.83% down from the prior year.
  • Cash & Current Investments reached $154.5 million in Q4 2025 per SNDX's latest filing, down from $436.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $455.2 million in Q2 2025 and bottomed at $57.5 million in Q1 2023.
  • Average Cash & Current Investments over 5 years is $214.6 million, with a median of $161.1 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 333.01% in 2022, then crashed 69.53% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $222.2 million in 2021, then tumbled by 62.67% to $83.0 million in 2022, then surged by 264.41% to $302.3 million in 2023, then crashed by 45.71% to $164.1 million in 2024, then decreased by 5.83% to $154.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $154.5 million in Q4 2025, $436.0 million in Q3 2025, and $455.2 million in Q2 2025.